Expenditures for First- and Second-Generation Tyrosine Kinase Inhibitors Before and After Transition of Imatinib to Generic Status

Lignende værker

• Anticipated Impact of Generic Imatinib Market Entry on the Costs of Tyrosine Kinase Inhibitors
  af: Bloudek, Lisa M., et al.
  Udgivet: (2015)
• Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status
  af: Bhargava, Pankaj, et al.
  Udgivet: (2011)
• Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors
  af: Nteliopoulos, Georgios, et al.
  Udgivet: (2019)
• Association of Generic Imatinib Availability and Pricing With Trends in Tyrosine Kinase Inhibitor Use in Patients With Chronic Myelogenous Leukemia
  af: Lyman, Gary H., et al.
  Udgivet: (2020)
• Second-generation inhibitors of Bruton tyrosine kinase
  af: Wu, Jingjing, et al.
  Udgivet: (2016)